

# Using comprehensive FLASH-RBE simulations to assess the potential clinical gain of FLASH proton therapy

Steven van de Water <sup>1\*</sup>, Silvia Fabiano <sup>2</sup>, Nicola Bizzocchi <sup>1</sup>, Sairos Safai <sup>1</sup>, Damien C. Weber <sup>1,2,3</sup>, Alejandro Mazal <sup>4</sup>, Jan Unkelbach <sup>2</sup>, Antony J. Lomax <sup>1,5</sup>

<sup>1</sup> Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Switzerland  
<sup>2</sup> Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland  
<sup>3</sup> Department of Radiation Oncology, University Hospital Bern, Bern, Switzerland  
<sup>4</sup> Centro de Protonterapia Quironsalud, Madrid, Spain.  
<sup>5</sup> Department of Physics, ETH Zürich, Zürich, Switzerland  
\* steven.vandewater@psi.ch

## PURPOSE


The ‘FLASH-RBE’ concept (Mazal *et al.* 2020 <sup>1</sup>) allows ultra-high dose rates to be translated into a quantitative dose-effect, by ascribing an RBE<1 (i.e. tissue sparing) to dose delivered at FLASH conditions. The purpose of this study was to:

- **Implement and extend the FLASH-RBE concept** for spot-scanned proton therapy to take into account **delivery dynamics, threshold dose, threshold dose rate, and reoxygenation time**
- Use FLASH-RBE to quantify the FLASH-effect and assess the **potential clinical gain of FLASH proton therapy** for different **patient cases, treatment planning strategies and varying FLASH parameters.**

## FLASH-RBE

### FLASH-RBE activation in normal-tissues

- ‘Moving window’ analysis on voxel-dose time structure (Figure 1):
  1. For normal-tissue voxels, FLASH effect activated when:
    - Dose  $\geq$  threshold dose AND dose rate  $\geq$  threshold dose rate
  2. When activated, for all subsequent dose delivered to same voxel *within reoxygenation time*, regardless of dose/dose-rate:
    - **FLASH-RBE < 1**
- For tumor voxels or non-FLASH dose:
  - **FLASH-RBE = 1**



**Figure 1.** Moving window to identify ‘FLASH activation’ (i.e. threshold dose delivered at threshold dose rate). If activated, all dose delivered within FLASH activation window and reoxygenation time is ascribed a FLASH-RBE < 1.

## METHODS

### Patient cases

• Nasal cavity case	superficial tumor	PTV: 280 cc
• Pancreas case	deep-seated tumor	PTV: 104 cc

### Spot-reduced treatment plans considered <sup>2</sup>

- **Bragg-peak-based IMPT:**
  - Single-field or multi-field
  - Upstream energy modulation (degrader) or downstream energy modulation (range-shifter plates)
  - Upstream multi-field IMPT plan = reference plan
- **Shoot-through (transmission) fields:**
  - Single-field or multi-field

### Delivery settings

- Theoretical spot-wise beam intensities Varian ProBeam
- Spot switching 3 ms
- Energy switching:
  - Upstream 250 ms
  - Downstream 50 ms
- Time between fields (i.e. gantry rotation) > reoxygenation time

### FLASH parameters investigated

- **FLASH activated RBE** 0.67 (i.e. 33% sparing)
- **Fraction doses** 10 or 20 Gy
- **FLASH dose thresholds** 5 or 10 Gy
- **FLASH dose rate thresholds** 40 or 100 Gy/s
- **Reoxygenation times** 200 or 500 ms

### Evaluation

- Normal-tissue integral dose (ID; excluding PTV):
  - **FLASH-effect:** ID reduction due to FLASH
  - **Clinical gain:** ID reduction compared with reference plan

## RESULTS

- FLASH effect was relatively low for conventional upstream energy-modulated Bragg-peak-based planning (see Figures 2 and 3):

### • Advantageous planning strategies for FLASH:


- Shoot-through/transmission planning
- Downstream energy modulation
- Fewer fields

### • Delivery/model parameters most affecting the FLASH effect:


- Higher fraction dose (strong effect)
- Lower FLASH dose threshold (strong effect)
- Lower FLASH dose rate thresholds (moderate effect)
- Longer reoxygenation time (weak effect)

- **Clinical gain was typically limited:**

- Shoot-through fields and downstream energy modulation (i.e. strong FLASH effect) result in considerably higher integral dose compared with the reference plan, for the deep-seated pancreas tumor in particular



**Figure 2.** FLASH normal-tissue integral dose reductions for the nasal-cavity case (top) and pancreas case (bottom), for different planning strategies and FLASH parameters (fraction dose, threshold dose and dose rate, and reoxygenation time). Dashed black lines indicate the normal-tissue ID reduction if the reference IMPT plan would be used instead.



**Figure 3.** Physical dose distributions (top row) and FLASH-RBE dose reductions (bottom row) for 20 Gy fraction dose, 5 Gy threshold dose, 40 Gy/s dose rate threshold, and 200 ms reoxygenation time. White contours indicate PTV (solid) and organs-at-risk (dotted).

## CONCLUSION

- **Substantial FLASH effects** could only be achieved when using **shoot-through fields or downstream energy modulation**, combined with **high fraction doses**

- **Planning/delivery strategies maximizing the FLASH effect** typically result in **increased normal-tissue dose compared with conventional IMPT planning**

**For the FLASH parameters studied here, our results indicate that PBS proton based FLASH is unlikely to be more effective for general normal-tissue sparing (integral dose) than conventional IMPT. Further investigations are required to assess its effectiveness for more selective sparing.**

## REFERENCES AND ACKNOWLEDGMENTS

- <sup>1</sup> A. Mazal *et al.*, FLASH and minibeam in radiation therapy: the effect of microstructures on time and space and their potential application to protontherapy, Br. J. Radiol. 2020.  
<sup>2</sup> S. van de Water *et al.*, Towards FLASH proton therapy: the impact of treatment planning and machine characteristics on achievable dose rates, Acta Oncol. 2019.

This work was supported by the EU-H2020 project ‘INSPIRE’ (INfraStructure in Proton International REsearch; grant ID: 730983)